reports
Inari Amertron Bhd: 1 director
A director at Inari Amertron Bhd sold 2,000,000 shares at 0.000MYR and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cl...
Change in number of shares and votes in HMS Networks
Change in number of shares and votes in HMS Networks As previously announced, HMS Networks has carried out a directed share issue. The directed share issue has resulted in a change in the number of shares and votes in HMS Networks. Prior to the directed share issue, the total number of shares in HMS Networks amounted to 46,818,868, corresponding to 46,818,868 votes. The number of shares and votes has as a result of the directed share issue increased by 3,500,000. As of April 30, 2024, the total number of shares in HMS Networks amounts to 50,318,868, corresponding to 50,318,868 votes.1 ...
Förändring av antalet aktier och röster i HMS Networks
Förändring av antalet aktier och röster i HMS Networks HMS Networks har som tidigare offentliggjorts genomfört en riktad nyemission av aktier. Emissionen har resulterat i en förändring av antalet aktier och röster i HMS Networks. Före emissionen fanns sammanlagt 46 818 868 aktier i HMS Networks, motsvarande 46 818 868 röster. Antalet aktier och röster har genom emissionen ökat med 3 500 000. Per den 30 april 2024 finns det sammanlagt 50 318 868 aktier i HMS Networks, motsvarande 50 318 868 röster.1 För mer information, vänligen kontakta:Staffan Dahlström, VD HMS, ...
KKR’s Henry McVey Says Insurance CIOs Plan to Increase Allocations to ...
NEW YORK--(BUSINESS WIRE)-- KKR, a leading global investment firm, today released “No Turning Back,” a new Insights piece by Henry McVey, CIO of KKR’s Balance Sheet and Head of Global Macro and Asset Allocation (GMAA). Based on a proprietary survey of nearly 50 Chief Investment Officers (CIOs) who collectively oversee over more than $8 trillion dollars in assets, the report examines how leading insurance companies are navigating and evolving their asset allocation priorities for today’s more volatile interest rate environment. Specifically, McVey notes that allocations to non-traditional inv...
ATHA Energy Completes Angilak Project Equipment and Supply Mobilizatio...
ATHA Energy Completes Angilak Project Equipment and Supply Mobilization, Update on Commencement of Diamond Drilling HIGHLIGHTS: The Company has completed its equipment and supply mobilization to its 100%-owned Angilak Project in Nunavut, Canada.Mobilization included the delivery of two X10 Diamond Drills (), which are anticipated to nearly double daily meterage production compared to previous drilling campaigns conducted on the Angilak Project.The mobilization was completed in support of the 2024 Exploration Program at the Angilak Project, scheduled to commence Phase I (Diamond Drilling)...
The recording of Šiaulių Bankas Investor Conference Webinar of introdu...
The recording of Šiaulių Bankas Investor Conference Webinar of introducing the financial results for Q1 2024 During the Investor Conference Webinar by Vytautas Sinius, CEO, Donatas Savickas, CFO, Tomas Varenbergas, Head of Investment Management Division and Indre Genytė-Pikčienė, Chief Economist. introduced the Bank’s financial results for Q1 2024 and recent developments and answered the participant questions afterwards. The recording of it can be found on Nasdaq youtube channel . Presentation and the recording of webinar are also posted on the Bank's website Šiaulių bankas th...
Šiaulių banko 2024 metų pirmojo ketvirčio finansinių rezultatų pristat...
Šiaulių banko 2024 metų pirmojo ketvirčio finansinių rezultatų pristatymo internetiniame seminare įrašas Internetiniame seminare Banko Administracijos vadovas Vytautas Sinius, Finansų tarnybos vadovas Donatas Savickas, Investicijų valdymo tarnybos vadovas Tomas Varenbergas ir vyriausioji ekonomistė Indrė Genytė-Pikčienė komentavo banko 2024 m. I ketvirčio finansinius veiklos rezultatus bei aktualijas ir po pristatymo atsakė į dalyvių klausimus. Seminaro įrašą (anglų kalba) galima peržiūrėti Nasdaq youtube paskyroje . Pristatymas ir seminaro įrašas (anglų kalba) taip pat patalpintas Banko ...
AirSculpt Technologies Announces First Quarter 2024 Earnings Release D...
AirSculpt Technologies Announces First Quarter 2024 Earnings Release Date and Conference Call MIAMI BEACH, Fla., April 30, 2024 (GLOBE NEWSWIRE) -- AirSculpt Technologies, Inc. (“AirSculpt”) (NASDAQ: AIRS), a national provider of premium body contouring procedures, today announced it will report first quarter 2024 financial results before market open on Friday, May 10, 2024, to be followed by a conference call on the same day at 8:30 a.m. Eastern Time. The conference call can be accessed by dialing 1-877-407-9716 (toll-free domestic) or 1-201-493-6779 (international) using the conference...
Perspective Therapeutics Selected by FDA to Participate in the CDRP Pr...
Perspective Therapeutics Selected by FDA to Participate in the CDRP Program to Expedite Chemistry, Manufacturing, and Controls Development Readiness for VMT-α-NET in NETs SEATTLE, April 30, 2024 (GLOBE NEWSWIRE) -- (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announces the selection of investigational product [212Pb]VMT‐α‐NET for the treatment of certain patients with neuroendocrine tumors (“NETs”) by the U.S. Food and Drug Administration (“FDA”) to participate in the Chemistry, Manufactur...
ProMIS Neurosciences Publishes Study Highlighting Oligomer Selectivity...
ProMIS Neurosciences Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies Study results support differentiation of PMN310 from other amyloid-beta-directed antibodies CAMBRIDGE, Massachusetts and TORONTO, Ontario, April 30, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA)...
LGI Homes Reports First Quarter 2024 Results
LGI Homes Reports First Quarter 2024 Results THE WOODLANDS, Texas, April 30, 2024 (GLOBE NEWSWIRE) -- LGI Homes, Inc. (NASDAQ: LGIH) today announced financial results for the three months ended March 31, 2024. First Quarter 2024 Highlights Home sales revenues of $390.9 millionHome closings of 1,083Average sales price per home closed of $360,897Gross margin as a percentage of home sales revenues of 23.4%Adjusted gross margin (non-GAAP) as a percentage of home sales revenues of 25.3%Net income before income taxes of $23.1 millionNet income of $17.1 million, or $0.72 basic EPS and $0....
Playboy Enters into Multiple New China License Agreements
Playboy Enters into Multiple New China License Agreements Represents Major Step by China Joint Venture to Reinvigorate Playboy in China LOS ANGELES, April 30, 2024 (GLOBE NEWSWIRE) -- PLBY Group, Inc. (NASDAQ: PLBY) (“PLBY Group” or the “Company”), a leading pleasure and leisure lifestyle company and owner of Playboy, announced that its China joint venture (the “China JV”) has entered into several new licensing agreements with unrelated, third-parties based in China, representing a major step by the China JV to reinvigorate the Playboy brand in China. The series of new agreements is hig...
ZeroFox Threat Intelligence and Attack Surface Experts to Present at 2...
ZeroFox Threat Intelligence and Attack Surface Experts to Present at 2024 RSA Conference ZeroFox to showcase external cybersecurity platform with newly-released external attack surface management module WASHINGTON, April 30, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: ZFOX), a leading provider of external cybersecurity, is exhibiting and speaking at the 2024 RSA Conference in San Francisco, California from May 6-9th. Visit ZeroFox at Booth 1135 to learn how to see and secure all external assets with ZeroFox’s External Attack Surface Management solution, which is generally available as of today. ...
Gritstone bio Highlights the Durability and Potential Broad Utility of...
Gritstone bio Highlights the Durability and Potential Broad Utility of its Self-amplifying mRNA (samRNA) COVID-19 Vaccine at ESCMID Global 2024 -- IgG levels and neutralizing antibodies against variants of concern persisted for at least 12 months, consistent with previous findings -- -- Antigen-specific T cell responses increased in the majority of participants studied, including those living with HIV, after administration of any of the samRNA constructs -- -- Comprehensive data set demonstrates a consistent and strong immunogenicity profile across multiple patient populations in South Af...
First National Corporation Reports First Quarter Financial Results
First National Corporation Reports First Quarter Financial Results STRASBURG, Va., April 30, 2024 (GLOBE NEWSWIRE) -- First National Corporation (the “Company” or “First National”) (NASDAQ: FXNC), the bank holding company of First Bank (the “Bank”), reported unaudited consolidated net income of $3.2 million and diluted earnings per common share of $0.51 for the three months ended March 31, 2024. FIRST QUARTER HIGHLIGHTS Key highlights of the three months ended March 31, 2024 are as follows. Comparisons are to the three-month period ended December 31, 2023, unless otherwise stated: Retu...
Aclaris Therapeutics to Announce First Quarter 2024 Financial Results ...
Aclaris Therapeutics to Announce First Quarter 2024 Financial Results on May 7, 2024 and to Provide Corporate Update WAYNE, Pa., April 30, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced it will report financial results for the first quarter 2024 on Tuesday, May 7, 2024, after the closing of the U.S. financial markets. Management will conduct a conference call at 5:00 p.m. ET on the same day to provide a corporate update. The confere...
Broadwind Announces First Quarter 2024 Results Conference Call and Web...
Broadwind Announces First Quarter 2024 Results Conference Call and Webcast Date CICERO, Ill., April 30, 2024 (GLOBE NEWSWIRE) -- Broadwind (Nasdaq: BWEN), a diversified precision manufacturer of specialized components and solutions serving global markets, today announced that it will issue first quarter 2024 results before the market opens on Tuesday, May 14, 2024. A conference call will be held that same day at 11:00 a.m. ET to review the Company’s financial results, discuss recent events and conduct a question-and-answer session. A webcast of the conference call and accompanying presen...
Plug to Announce 2024 First Quarter Results
Plug to Announce 2024 First Quarter Results LATHAM, N.Y., April 30, 2024 (GLOBE NEWSWIRE) -- Plug Power Inc. (NASDAQ: PLUG), a global leader in comprehensive hydrogen solutions for the green hydrogen economy, will announce its 2024 first quarter results on Thursday May 9, 2024. Join the call: Date: May 9, 2024Time: 8:30 AM ETToll-free: 877-407-9221 / Direct webcast: The webcast can also be accessed directly from the Plug homepage (). A playback of the call will be available online for a period following the call. About Plug Plug is building an end-to-end green h...
Eton Pharmaceuticals Announces Submission to FDA of New Drug Applicati...
Eton Pharmaceuticals Announces Submission to FDA of New Drug Application for ET-400 (Hydrocortisone Oral Solution) - Company anticipates 10-month review for potential approval in Q1 2025 -- Eton expects ET-400 and Alkindi Sprinkle® to achieve potential combined peak sales of more than $50 million annually -- Product has patent protection through 2043 - DEER PARK, Ill., April 30, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today ann...
Climb Channel Solutions' Commitment to Excellence Recognized with Mult...
Climb Channel Solutions' Commitment to Excellence Recognized with Multiple Prestigious Awards in Q1 2024 EATONTOWN, N.J., April 30, 2024 (GLOBE NEWSWIRE) -- Climb Channel Solutions, an international specialty technology distributor and wholly owned subsidiary of Climb Global Solutions, Inc. (NASDAQ: CLMB) is proud to announce its exceptional recognition in the first quarter of 2024 with ten awards from industry leaders. The recognition reaffirms Climb Channel Solutions' dedication to delivering unparalleled service and support to its partners and customers across the globe. "We are ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.